Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
CAPR Stock Chart & Stats
$6.20
-$0.36(-2.53%)
At close: 4:00 PM EST
$6.20
-$0.36(-2.53%)
Day’s Range― - ―
52-Week Range$5.68 - $22.90
Previous CloseN/A
Volume187.65K
Average Volume (3M)1.27M
Market Cap
$280.25M
Enterprise Value$335.51M
Total Cash (Recent Filing)$122.80M
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Nov 12, 2025EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding45,716,976
10 Day Avg. Volume1,006,376
30 Day Avg. Volume1,271,982
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)3.34
Price to Sales (P/S)21.82
P/FCF Ratio-11.70
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue25.05
Enterprise Value/Gross Profit28.52
Enterprise Value/Ebitda-4.76
Forecast
1Y Price Target
$22.17Price Target Upside257.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyDeramiocel shows a real effect on cardiac tissue, with 21 out of 22 cardiac parameters favoring its use, indicating potential benefits for cardiac function.
Financial StabilityCapricor maintains a strong cash balance sheet, which supports its ongoing development and regulatory efforts.
Regulatory AdvantageRegulatory alignment between Capricor and the FDA positions deramiocel favorably for BLA resubmission.
Bears Say
FDA FeedbackAlthough the FDA cited a lack of consistency in secondary and exploratory cardiac-related endpoints, 21 out of 22 cardiac parameters favored deramiocel, suggesting a real effect on cardiac tissue.
Study ResultsThe HOPE-2 study failed to demonstrate efficacy in a prespecified 12-month change in the mid-level (elbow) dimension of the PUL 1.2 metric according to the FDA.
Capricor Therapeutics News
CAPR FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was $5.68 and its highest was $22.90 in the past 12 months.
What is Capricor Therapeutics’s market cap?
Capricor Therapeutics’s market cap is $280.25M.
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 17 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.476 by -$0.094.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -0.55.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 45,716,976 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.476. Following the earnings report the stock price went up 2.813%.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Currently, no hedge funds are holding shares in CAPR
Capricor Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.17 (257.58% Upside)
$22.17 (257.58% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.76%
12-Months-Change
Fundamentals
Return on Equity
-120.15%
Trailing 12-Months
Asset Growth
248.95%
Trailing 12-Months
Company Description
Capricor Therapeutics
Capricor Therapeutics (CAPR) is a biotechnology company focused on developing innovative therapies for the treatment of rare cardiovascular diseases and disorders. The company specializes in regenerative medicine, particularly using its proprietary exosome platform technology derived from cardiac stem cells. Capricor's core products include CAP-1002, an investigational drug aimed at treating Duchenne muscular dystrophy and other related conditions, as well as additional therapeutic candidates targeting various indications in the cardiovascular space.
CAPR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted Capricor Therapeutics' strong cash position and progress in its exosome program but faced significant challenges with the FDA's complete response letter, increased expenses, and zero revenue, resulting in a net loss. The regulatory delays and lack of clarity on the approval path for Deramiocel contributed to a negative outlook.View all CAPR earnings summariesCAPR Stock 12 Month Forecast
Average Price Target
$22.17
▲(257.58% Upside)
Technical Analysis
Ownership Overview
1.28% Insiders
7.36% Mutual Funds
0.48% Other Institutional Investors
83.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---